AC2993 Program Update

• Phase 3 AMIGO pivotal trials enrolled

  • First study targeted to complete in 1H 2003

• Initial open-label data reported in December 2002

  • Mean reductions in HbA1c of 1.5% at 12 weeks
  • No increase in mean body weight

• NDA submission targeted for 2004

Previous slide

Next slide

Back to first slide

View graphic version